Search

Displaying results 1971 - 1980 of 10000 in total
  1. Drug

    Vericiguat

    go.drugbank.com/drugs/DB15456
    ApprovedInvestigational

    [L31178] Although not the first sGC stimulator to be granted FDA approval ([riociguat] was approved in 2013 for use in pulmonary hypertension),[L3955] vericiguat is unique amongst its peers in that modifications … to its structure have dramatically decreased its susceptibility to oxidative metabolism,[A227458] resulting in a relatively long half-life and allowing for once-daily dosing.

    Categories: Vasodilators Used in Cardiac Diseases
  2. Drug

    Potassium cation

    go.drugbank.com/drugs/DB01345
    Approved

    The ability of cells to produce electrical discharge is critical for body functions such as neurotransmission, muscle contraction, and heart function. … The balance between potassium and sodium is maintained by ion pumps in the cell membrane.

    Mixtures: Telom-X-gene, POLİFLEKS LAKTATLI RİNGER IV İNFÜZYON İÇİN ÇÖZELTİ, 1000 CC SETLICategories: Potassium Salt
  3. Drug

    Amphetamine

    go.drugbank.com/drugs/DB00182
    ApprovedIllicitInvestigational

    Amphetamine structure presents one chiral center and it exists in the form of dextro- and levo-isomers.[A18540] The first product of Smith, Kline and French was approved by the FDA on 1976. … It was previously used for a large variety of conditions and this changed until this point where its use is highly restricted.

    Mixtures: Adderall XR, Adderall XRCategories: Psychostimulants, Agents Used for ADHD and Nootropics, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  4. Drug

    Urethane

    go.drugbank.com/drugs/DB04827
    ApprovedWithdrawn

    Urethane, formerly marketed as an inactive ingredient in Profenil injection, was determined to be carcinogenic and was removed from the Canadian, US, and UK markets in 1963.

  5. Drug

    Nateglinide

    go.drugbank.com/drugs/DB00731
    Approved

    Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). … Meglitnides may have a neutral effect on weight or cause a slight increase in weight.

    Categories: Drugs Used in Diabetes
  6. Drug

    Cangrelor

    go.drugbank.com/drugs/DB06441
    ApprovedInvestigational

    Cangrelor was approved by the FDA in June 2015 for intravenous application. … Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors.

  7. Target

    DNA damage-inducible transcript 4 protein

    go.drugbank.com/bio_entities/BE0003445
    TargetHumans

    Required for normal neuron migration during embryonic brain development. Plays a role in neuronal cell death … Required for mTORC1-mediated defense against viral protein synthesis and virus replication (By similarity).

    Synonyms: Protein regulated in development and DNA damage response 1
  8. Drug

    Cod liver oil

    go.drugbank.com/drugs/DB11321
    ApprovedNutraceuticalVet approved

    It is used as an adjunct treatment and preventative therapy of rickets, osteomalacia and osteoporosis while meeting the consumption criteria. … Cod liver oil is extracted from the liver of cod fish and mainly consists of omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).

    Mixtures: CURACID Dermal for cuts and burns, Desitin - Salbe
  9. Drug

    Abacavir

    go.drugbank.com/drugs/DB01048
    ApprovedInvestigational

    In vivo, abacavir sulfate dissociates to its free base, abacavir. … Chemically, it is a synthetic carbocyclic nucleoside and is the enantiomer with 1S, 4R absolute configuration on the cyclopentene ring.

    Mixtures: N/ACategories: Antivirals used in combination for the treatment of HIV infections, Antivirals for Systemic Use
  10. Drug

    Bezlotoxumab

    go.drugbank.com/drugs/DB13140
    Approved

    [L46976] On November 22, 2016, the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended the granting of a marketing authorization. … [L46976] First approved by the FDA on October 21, 2016,[A260106] bezlotoxumab is used to reduce the recurrence of _C. difficile_ infection.

    Categories: Antiinfectives for Systemic Use